Continued here:
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh